Trevi Therapeutics (TRVI)

[Long_Holder]

TRVI
Updated information from the most recent corporate presentation.
I love this stock, been accumulating for about a year.

Prurigo Nodularis – PRISM Trial Update (main indication)
• Approximately 155 subjects enrolled as of 8/13/2020
• COVID-19 screening restrictions lifted in May/June for sites and had
strong enrollment since
• Positive sample size re-estimation read-out this summer. Trial moving
forward with an increase in the sample size to maintain the power
(n=360)
• We have opened more than 60 sites in the US and Europe
• Guidance: Complete Enrollment - Q3 2021
Top-line Data - Q4 2021
• More than 95% of subjects have continued into the one-year open label
extension study

This is a small float, under valued ticker, with Cash position to fund operations into the first half of 2022.

Float 12.0M Shares
Outstanding 18.2M
Institutions Holding Shares 16
% Held by Institutions 79.72%